Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Less-expensive diuretics found superior in treatment of hypertension

17.12.2002


A major clinical trial of blood pressure medications has concluded that an inexpensive diuretic (water pill) is more effective in treating high blood pressure and preventing cardiovascular disease than newer more expensive medications.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), conducted from February 1994 though March 2002, compared the drugs for use in starting treatment for high blood pressure.

"The preferred drug is the diuretic for three reasons. It provides better control of hypertension; it reduces complications from hypertension--particularly heart failure-- more effectively; and it is 10 to 20 times less expensive than the other drugs used in the trial," said Curt Furberg, M.D., Ph.D., of Wake Forest University Baptist Medical Center, chairman of the study’s steering committee.



ALLHAT is the largest study ever to compare different types of hypertension drugs. It included more than 33,000 participants age 55 years or older at 623 clinical sites in North America. All the patients had hypertension and at least one other coronary heart disease risk factor. Approximately 50 percent of the participants were women and 35 percent were African-American.

"The bottom line is ALLHAT has shown that it matters which drug you use to control hypertension," said Furberg.

Participants were randomly assigned to receive the diuretic chlorthalidone, amlodipine (a calcium channel blocker sold under the name Norvasc) or lisinopril, (an angiotensin-converting enzyme (ACE) inhibitor sold under the names Prinivil and Zestril.)

In 2000, another drug used in the trial, doxazosin (an alpha-blocker sold under the name Cardura) was pulled from the trial because it was determined early in ALLHAT that it was not as effective as the less expensive diuretic medication.

The study does not recommend that patients stop taking their medication if they are using a drug other than a diuretic. However they are encouraged to speak with their physicians about adding or switching to a diuretic for their treatment.

ALLHAT’s findings indicate that most patients will need more than one drug to adequately control their blood pressure and one of the drugs should be a diuretic. The National Heart, Lung and Blood Institute, part of the National Institutes of Health, supported the study.


Contact: Jim Steele, jsteele@wfubmc.edu, Jonnie Rohrer, ´jrohrer@wfubmc.edu, Karen Richardson, krchrdsn@wfubmc.edu or Barbara Hahn, bhahn@wfubmc.edu, 716-4587.

Jim Steele | EurekAlert!
Further information:
http://www.wfubmc.edu/

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New pop-up strategy inspired by cuts, not folds

27.02.2017 | Materials Sciences

Sandia uses confined nanoparticles to improve hydrogen storage materials performance

27.02.2017 | Interdisciplinary Research

Decoding the genome's cryptic language

27.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>